Skip to main content
SpringerLink
Log in

Ovarian Cancer

  • Chapter
  • First Online:
The Molecular Basis of Human Cancer

  • 3129 Accesses

Abstract

Ovarian carcinomas account for more deaths annually than any other gynecological cancer in the US. More than twice as many women die of ovarian cancer than endometrial cancer in spite of the fact that cancer of the endometrium is more frequent than that of the ovary. The 5-year survival of patients affected by these tumors has improved only modestly, from 45.4 to 48.6 % during the last two decades. The high mortality associated with ovarian carcinomas is due largely to the hidden anatomical location of the ovaries, which complicates the detection of abnormalities on physical examination, and the fact that these tumors typically remain asymptomatic until they spread outside the ovary, at which time they are difficult to eradicate. Hopefully, advances in our understanding of the histogenesis of ovarian epithelial tumors as well as of their underlying molecular mechanisms will lead to more effective strategies aimed at their early detection and prevention. This, in turn, should have a major impact on the morbidity and mortality associated with these tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Chan JK, Cheung MK, Husain A, et al. Patterns and progress in ovarian cancer over 14 years. Obstet Gynecol. 2006;108:521–8.

    Article  PubMed  Google Scholar 

  2. Cheng W, Liu J, Yoshida H, Rosen D, Naora H. Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. Nat Med. 2005;11:531–7.

    Article  CAS  PubMed  Google Scholar 

  3. Obata K, Morland SJ, Watson RH, et al. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res. 1998;58:2095–7.

    CAS  PubMed  Google Scholar 

  4. Sato N, Tsunoda H, Nishida M, et al. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst and clear cell carcinoma of the ovary. Cancer Res. 2000;60:7052–6.

    CAS  PubMed  Google Scholar 

  5. Caduff RF, Svoboda-Newman SM, Ferguson AW, Johnston CM, Frank TS. Comparison of mutations of Ki-RAS and p53 immunoreactivity in borderline and malignant ovarian tumors. Am J Surg Pathol. 1999;23:323–8.

    Article  CAS  PubMed  Google Scholar 

  6. Mok SC-HB. Mutation of k-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res. 1993;53:1489–92.

    CAS  PubMed  Google Scholar 

  7. Sieben NL, Macropoulos P, Roemen GM, et al. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumors. J Pathol. 2004;202:336–40.

    Article  CAS  PubMed  Google Scholar 

  8. Singer G, Kurman RJ, Chang HW, Cho SK, Shih I-M. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol. 2002;160:1223–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Singer G, Oldt III R, Cohen Y, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst. 2003;95:484–6.

    Article  CAS  PubMed  Google Scholar 

  10. Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010;363:1532–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Bonome T, Lee J-Y, Park D-C, et al. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res. 2005;65:10602–12.

    Article  CAS  PubMed  Google Scholar 

  12. Tsuda H, Ito YM, Ohashi Y, et al. Identification of overexpression and amplification of ABCF2 in clear cell ovarian adenocarcinomas by cDNA microarray analyses. Clin Cancer Res. 2005;11:6880–8.

    Article  CAS  PubMed  Google Scholar 

  13. Wamunyokoli FW, Bonome T, Lee J-Y, et al. Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance. Clin Cancer Res. 2006;12:690–700.

    Article  CAS  PubMed  Google Scholar 

  14. Zorn KK, Bonome T, Gangi L, et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res. 2005;11:6422–30.

    Article  CAS  PubMed  Google Scholar 

  15. Jazaeri AA, Awtrey CS, Chandramouli GVR, et al. Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res. 2005;11:6300–10.

    Article  CAS  PubMed  Google Scholar 

  16. Ouellet V, Guyot M-C, Le Page C, et al. Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer. Int J Cancer. 2006;119:599–607.

    Article  CAS  PubMed  Google Scholar 

  17. Pike MC, Pearce CL, Peters R, et al. Hormonal factors and the risk of invasive ovarian cancer: a population-based case-control study. Fertil Steril. 2004;83:186–95.

    Article  Google Scholar 

  18. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol. 1992;136:1184–203.

    CAS  PubMed  Google Scholar 

  19. Pike MC. Age-related factors in cancers of the breast, ovary, and endometrium. J Chronic Dis. 1987;40:59S–69.

    Article  PubMed  Google Scholar 

  20. Fathalla MF. Factors in the causation and incidence of ovarian cancer. Gynecol Surv. 1972;27:751–77.

    Article  CAS  Google Scholar 

  21. Zhou H, Luo MP, Schonthal AH, et al. Effect of reproductive hormones on ovarian epithelial tumors: I. Effect on cell cycle activity. Cancer Biol Ther. 2002;1:300–6.

    Article  CAS  PubMed  Google Scholar 

  22. Rodriguez GC, Nagarsheth NP, Lee KL, et al. Progestin-induced apoptosis in the macaque ovarian epithelium: differential regulation of the transforming growth factor beta. J Natl Cancer Inst. 2002;94:50–60.

    Article  CAS  PubMed  Google Scholar 

  23. Cramer DW, Barbieri RL, Fraer AR, Harlow BL. Determinants of early follicular phase gonadotrophin and estradiol concentrations in women of late reproductive age. Hum Reprod. 2002;17:221–7.

    Article  CAS  PubMed  Google Scholar 

  24. Risch HA. Hormonal etiology of epithelial ovarian cancer, with hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst. 1998;90:1774–86.

    Article  CAS  PubMed  Google Scholar 

  25. Helzlsouer KJ, Alberg AJ, Gordon GB, et al. Serum gonadotropins and steroid hormones and the development of ovarian cancer. JAMA. 1995;274:1926–30.

    Article  CAS  PubMed  Google Scholar 

  26. Ness RB, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst. 1999;91:1459–67.

    Article  CAS  PubMed  Google Scholar 

  27. Cook LS, Kamb ML, Weiss NS. Perineal powder exposure and the risk of ovarian cancer. Am J Epidemiol. 1997;145:459–65.

    Article  CAS  PubMed  Google Scholar 

  28. Cramer DW, Liberman RF, Titus-Ernstoff L, et al. Genital talc exposure and risk of ovarian cancer. Int J Cancer. 1999;81:351–6.

    Article  CAS  PubMed  Google Scholar 

  29. Gertig DM, Hunter DJ, Cramer DW, et al. Prospective study of talc use and ovarian cancer. J Natl Cancer Inst. 2000;92:351–6.

    Article  Google Scholar 

  30. Ness RB, Grisso J, Cottreau C, et al. Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology. 2000;11:111–7.

    Article  CAS  PubMed  Google Scholar 

  31. Whittemore AS, Wu ML, Pafenbarger RS, et al. Personal and environmental characteristics related to epithelial ovarian cancer. Am J Epidemiol. 1988;128:1228–40.

    CAS  PubMed  Google Scholar 

  32. Wong C, Hempling RE, Piver MS, Natarajan N, Mettlin CJ. Perineal talc exposure and subsequent epithelial ovarian cancer. Obstet Gynecol. 1999;93:372–6.

    CAS  PubMed  Google Scholar 

  33. Brinton LA, Gridley G, Persson I, Baron J, Bergqvist A. Cancer risk after a hospital discharge diagnosis of endometriosis. Am J Obstet Gynecol. 1997;176:572–9.

    Article  CAS  PubMed  Google Scholar 

  34. Heaps JM, Nieberg RK, Berek JS. Malignant neoplasms arising in endometriosis. Obstet Gynecol. 1990;75:1023–8.

    CAS  PubMed  Google Scholar 

  35. Ness RB. Endometriosis and ovarian cancer: thoughts on shared pathophysiology. Am J Obstet Gynecol. 2003;189:280–94.

    Article  PubMed  Google Scholar 

  36. Prefumo F, Todeschini F, Fulcheri E, Venturini PL. Epithelial abnormalities in cystic ovarian endometriosis. Gynecol Oncol. 2002;84:280–4.

    Article  PubMed  Google Scholar 

  37. Prowse AH, Manek S, Varma R, et al. Molecular genetic evidence that endometriosis is a precursor of ovarian cancer. Int J Cancer. 2006;119:556–62.

    Article  CAS  PubMed  Google Scholar 

  38. Vignali M, Infantino M, Matrone R, et al. Endometriosis: novel etiopathogenetic concepts and clinical perspectives. Fertil Steril. 2002;78:665–78.

    Article  PubMed  Google Scholar 

  39. Risch HA, Howe GR. Pelvic inflammatory disease and the risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 1995;4:447–51.

    CAS  PubMed  Google Scholar 

  40. Shu XO, Brinton LA, Gao YT, Yuan JM. Population-based case-control study of ovarian cancer in Shanghai. Cancer Res. 1989;49:3670–4.

    CAS  PubMed  Google Scholar 

  41. Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, et al. Aspirin and epithelial ovarian cancer. Prev Med. 2001;33:682–7.

    Article  CAS  PubMed  Google Scholar 

  42. Cramer DW, Harlow BL, Titus-Ernstoff L, et al. Over-the-counter analgesics and risk of ovarian cancer. Lancet. 1998;351:104–7.

    Article  CAS  PubMed  Google Scholar 

  43. Moysich KB, Mettlin C, Piver MS, et al. Regular use of analgesic drugs and ovarian cancer risk. Cancer Epidmiol Biomarkers Prev. 2001;10:903–6.

    CAS  Google Scholar 

  44. Tavani A, Gallus S, La Vecchia C, et al. Aspirin and ovarian cancer: an Italian case-control study. Ann Oncol. 2000;11:1171–3.

    Article  CAS  PubMed  Google Scholar 

  45. Jordan SJ, Whiteman DC, Purdie DM, Green AC, Webb PM. Does smoking increase risk of ovarian cancer? A systematic review. Gynecol Oncol. 2006;103:1122–9.

    Article  CAS  PubMed  Google Scholar 

  46. Pan SY, Ugnat AM, Mao Y, Wen SW, Johnson KC. Association of cigarette smoking with the risk of ovarian cancer. Int J Cancer. 2004;111:124–30.

    Article  CAS  PubMed  Google Scholar 

  47. Purdie DM, Webb PM, Siskind V, Bain CJ, Green AC. The different etiologies of mucinous and nonmucinous epithelial ovarian cancers. Gynecol Oncol. 2003;88:S145–8.

    Article  PubMed  Google Scholar 

  48. Risch HA, Marrett LD, Jain M, Howe GR. Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case-control study. Am J Epidemiol. 1996;144:363–72.

    Article  CAS  PubMed  Google Scholar 

  49. Genkinger JM, Hunter DJ, Spiegelman D, et al. A pooled analysis of 12 cohort studies of dietary fat, cholesterol and egg intake and ovarian cancer. Cancer Causes Control. 2006;17:273–85.

    Article  PubMed  Google Scholar 

  50. Cramer DW, Greenberg ER, Titus-Ernstoff L, et al. A case-control study of galactose consumption and metabolism in relation to ovarian cancer. Cancer Epidmiol Biomarkers Prev. 2000;9:95–101.

    CAS  Google Scholar 

  51. Fung WLA, Risch HA, McLaughlin J, et al. The N314D polymorphism of galactose-1-phosphate uridyl transferase does not modify the risk of ovarian cancer. Cancer Epidmiol Biomarkers Prev. 2003;12:678–80.

    CAS  Google Scholar 

  52. Qin L-Q, Xu J-Y, Wang P-Y, et al. Milk/dairy products consumption, galactose metabolism and ovarian cancer: meta-analysis of epidemiological studies. Eur J Cancer Prev. 2005;14:13–9.

    Article  PubMed  Google Scholar 

  53. Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer. 1996;77:2318–24.

    Article  CAS  PubMed  Google Scholar 

  54. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Brose MS, Rebbeck TR, Calzone KA, et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst. 2002;94:1365–72.

    Google Scholar 

  56. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast cancer linkage consortium. Lancet. 1994;343:692–5.

    Article  CAS  PubMed  Google Scholar 

  57. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The breast cancer linkage consortium. Am J Hum Genet. 1998;62:676–89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. King MC, Marks JH, Mandell JB, et al. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302:643–6.

    Article  CAS  PubMed  Google Scholar 

  59. Risch HA, MaLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001;68:700–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Thompson D, Easton DF, Breast Cancer Linkage Consortium. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet. 2001;68:410–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Chung DC, Rustgi AK. The hereditary nonpolyposis colorectal cancer syndrome: genetic and clinical implications. Ann Int Med. 2003;138:560–70.

    Article  CAS  PubMed  Google Scholar 

  62. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266:66–71.

    Article  CAS  PubMed  Google Scholar 

  63. ElShamy WM, Livingston DM. Identification of BRCA1-IRIS, a BRCA1 locus product. Nat Cell Biol. 2004;6:954–67.

    Article  CAS  PubMed  Google Scholar 

  64. Deng CX, Scott F. Role of the tumor suppressor gene Brca1 in genetic stability and mammary gland tumor formation. Oncogene. 2000;19:1059–64.

    Article  CAS  PubMed  Google Scholar 

  65. Scully R, Livingston DM. In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature. 2000;408:429–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Starita LM, Parvin JD. The multiple nuclear functions of BRCA1: transcription, ubiquitination and DNA repair. Curr Opin Cell Biol. 2003;15:345–50.

    Article  CAS  PubMed  Google Scholar 

  67. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 2002;108:171–82.

    Article  CAS  PubMed  Google Scholar 

  68. Zheng L, Li S, Boyer TG, Lee WH. Lessons learned from BRCA1 and BRCA2. Oncogene. 2000;19:6159–75.

    Article  CAS  PubMed  Google Scholar 

  69. Chodankar R, Kwang S, Sangiorgi F, et al. Cell-nonautonomous induction of ovarian and uterine serous cystadenomas in mice lacking a functional Brca1 in ovarian granulosa cells. Curr Biol. 2005;15:561–5.

    Article  CAS  PubMed  Google Scholar 

  70. Hu Y, Ghosh S, Amleh A, et al. Modulation of aromatase expression by BRCA1: a possible link to tissue-specific tumor suppression. Oncogene. 2005;24:8343–8.

    Article  CAS  PubMed  Google Scholar 

  71. Kramer JL, Velazquez IA, Chen BE, et al. Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers. J Clin Oncol. 2005;23:8629–35.

    Article  PubMed  Google Scholar 

  72. McLaughlin JR, Risch HA, Lubinski J, et al. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol. 2007;8:26–34.

    Article  CAS  PubMed  Google Scholar 

  73. Narod SA, Risch HA, Moslehi R, et al. Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med. 1998;339:424–428

    Google Scholar 

  74. Hong H, Yen HY, Brockmeyer A, et al. Changes in the mouse estrus cycle in response to Brca inactivation suggest a potential link between risk factors for familial and sporadic ovarian cancer. Cancer Res. 2010;70:221–8.

    Article  CAS  PubMed  Google Scholar 

  75. Scully RE. Ovarian tumors. Am J Pathol. 1977;87:686–718.

    CAS  PubMed  PubMed Central  Google Scholar 

  76. Rodriguez M, Dubeau L. Ovarian tumor development: insights from ovarian embryogenesis. Eur J Gynecol Oncol. 2001;22:175–83.

    CAS  Google Scholar 

  77. Dubeau L. The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: does the emperor have no clothes? Gynecol Oncol. 1999;72:437–42.

    Article  CAS  PubMed  Google Scholar 

  78. Colgan TJ, Murphy J, Cole DE, Narod S, Rosen B. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol. 2001;25:1283–9.

    Article  CAS  PubMed  Google Scholar 

  79. Leeper K, Garcia R, Swisher E, et al. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol. 2002;87:52–6.

    Article  PubMed  Google Scholar 

  80. Piek JM, van Diest PJ, Zweemer RP, et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 2001;195:451–6.

    Article  CAS  PubMed  Google Scholar 

  81. Tonin P, Weber B, Offit K, et al. Frequency of recurrent BRCA1 and BRCA2 mutations in 222 Ashkenazi Jewish breast cancer families. Nat Med. 1996;2:1179–83.

    Article  CAS  PubMed  Google Scholar 

  82. Lauchlan SC. The secondary mullerian system revisited. Int J Gynecol Pathol. 1994;13:73–9.

    Article  CAS  PubMed  Google Scholar 

  83. Quddus MR, Sung CJ, Lauchlan SC. Benign and malignant serous and endometrioid epithelium in the omentum. Gynecol Oncol. 1999;75:227–32.

    Article  CAS  PubMed  Google Scholar 

  84. Fredrickson TN. Ovarian tumors of the hen. Environ Health Perspect. 1987;73:35–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Dubeau L. The cell of origin of ovarian epithelial tumors. Lancet Oncol. 2008;9:1191–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Cornelison TL, Natarajan N, Piver MS, Mettlin CJ. Tubal ligation and the risk of ovarian carcinoma. Cancer Detect Prev. 1997;21:1–6.

    CAS  PubMed  Google Scholar 

  87. Cramer DW, Xu H. Epidemiologic evidence for uterine growth factors in the pathogenesis of ovarian cancer. Ann Epidemiol. 1995;5:310–4.

    Article  CAS  PubMed  Google Scholar 

  88. Green AC, Purdie DM, Bain CJ, et al. Tubal sterilization, hysterectomy and decreased risk of ovarian cancer. Survey of Women’s Health Group. Int J Cancer. 1997;71:948–51.

    Article  CAS  PubMed  Google Scholar 

  89. Hankinson SE, Hunter DJ, Colditz GA, et al. Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study. JAMA. 1993;270:2813–8.

    Article  CAS  PubMed  Google Scholar 

  90. Irwin KL, Weiss NS, Lee NC, Peterson HB. Tubal sterilization, hysterectomy, and the subsequent occurrence of epithelial ovarian cancer. Am J Epidemiol. 1991;134:362–9.

    CAS  PubMed  Google Scholar 

  91. Kreiger N, Sloan M, Cotterchio M, Parsons P. Surgical procedures associated with risk of ovarian cancer. Int J Epidemiol. 1997;26:710–5.

    Article  CAS  PubMed  Google Scholar 

  92. Loft A, Lidegaard O, Tabor A. Incidence of ovarian cancer after hysterectomy: a nationwide controlled follow up. Br J Obstet Gynaecol. 1997;104:1296–301.

    Article  CAS  PubMed  Google Scholar 

  93. Miracle-McMahill HL, Calle EE, Kosinski AS, et al. Tubal ligation and fatal ovarian cancer in a large prospective cohort study. Am J Epidemiol. 1997;145:349–57.

    Article  CAS  PubMed  Google Scholar 

  94. Rosenblatt KA, Thomas DB. Reduced risk of ovarian cancer in women with a tubal ligation or hysterectomy. Cancer Epidmiol Biomarkers Prev. 1996;5:933–5.

    CAS  Google Scholar 

  95. Weiss NS, Harlow BL. Why does hysterectomy without bilateral oophorectomy influence the subsequent incidence of ovarian cancer? Am J Epidemiol. 1986;124:856–8.

    CAS  PubMed  Google Scholar 

  96. Ludwig T, Fisher P, Ganesan S, Efstratiadis A. Tumorigenesis in mice carrying a truncated Brca1 mutation. Gene Dev. 2001;15:1188–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Connor F, Bertwistle D, Mee PJ, et al. Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation. Nat Genet. 1997;17:423–30.

    Article  CAS  PubMed  Google Scholar 

  98. Friedman LS, Thistlethwaite FC, Patel KJ, et al. Thymic lymphomas in mice with a truncating mutation in Brca2. Cancer Res. 1998;58:1338–43.

    CAS  PubMed  Google Scholar 

  99. McAllister KA, Bennett LM, Houle CD, et al. Cancer susceptibility of mice with a homozygous deletion in the COOH-terminal domain of the Brca2 gene. Cancer Res. 2002;62:990–4.

    CAS  PubMed  Google Scholar 

  100. Orsulic O, Soslow RA, Vitale-Cross LA, Gutkind JS, Varmus HE. Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell. 2002;1:53–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Flesken-Nikitin A, Choi K-C, Eng JP, Shmidt EN, Nikitin AY. Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. Cancer Res. 2003;63:3459–63.

    CAS  PubMed  Google Scholar 

  102. Dinulescu DM, Ince TA, Quade BJ, et al. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med. 2005;11:63–70.

    Article  CAS  PubMed  Google Scholar 

  103. Wu R, Hendrix-Lucas N, Kuick R, et al. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. Cancer Cell. 2007;11:321–33.

    Article  CAS  PubMed  Google Scholar 

  104. Clark-Knowles KV, Garson K, Jonkers J, Vanderhyden BC. Conditional inactivation of BBrca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changes. Exp Cell Res. 2007;313:133–45.

    Article  CAS  PubMed  Google Scholar 

  105. Burdette JE, Oliver RM, Ulyanov V, et al. Ovarian epithelial inclusion cysts in chronically superovulated cd1 and smad2 dominant negative mice. Endocrinology. 2007;148:3595–604.

    Article  CAS  PubMed  Google Scholar 

  106. Conolly DC, Bao R, Nikitin AY, et al. Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res. 2003;63:1389–97.

    Google Scholar 

  107. Pieretti-Vanmarcke R, Donahoe PK, Pearsall LA, et al. Mullerian inhibiting substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer. Proc Natl Acad Sci U S A. 2006;103:17426–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  108. Pieretti-Vanmarcke R, Donahoe PK, Szotek P, et al. Recombinant human mullerian inhibiting substance inhibits long term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo. Clin Cancer Res. 2006;12:1593–8.

    Article  CAS  PubMed  Google Scholar 

  109. Taylor JHC. Malignant and semimalignant tumors of the ovary. Surg Gynecol Obstet. 1929;48:204–8.

    Google Scholar 

  110. Aure JC, Hoeg K, Kolstad P. Clinical and histologic studies of ovarian carcinoma: long-term follow-up of 990 cases. Obstet Gynecol. 1971;37:1–9.

    CAS  PubMed  Google Scholar 

  111. Santesson L, Kottmeier HL. General classification of ovarian tumors. Ovarian cancer, U.I.C.C. Monograph Series. New York: Springer; 1968.

    Google Scholar 

  112. Serov SF, Scully RE, Sobin LH. Histological typing of ovarian tumors. In: International histological classification of tumours. Vol 9, Geneva; 1973.

    Google Scholar 

  113. Cheng PC, Gosewehr J, Kim TM, et al. Potential role of the inactivated X chromosome in ovarian epithelial tumor development. J Natl Cancer Inst. 1996;88:510–8.

    Article  CAS  PubMed  Google Scholar 

  114. Wan M, Li W-Z, Duggan B, et al. Telomerase activity in benign and malignant epithelial ovarian tumors. J Natl Cancer Inst. 1997;89:437–41.

    Article  CAS  PubMed  Google Scholar 

  115. Cheng PC, Schmutte C, Cofer KF, et al. Alterations in DNA methylation are early, but not initial events in ovarian tumorigenesis. Br J Cancer. 1997;75:396–402.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. Qu G, Dubeau L, Narayan A, Yu MC, Ehrlich M. Satellite DNA hypomethylation vs. overall genomic hypomethylation in ovarian epithelial tumors of different malignant potential. Mutat Res. 1999;423:91–101.

    Article  CAS  PubMed  Google Scholar 

  117. Cheng EJ, Kurman RJ, Wang M, et al. Molecular genetic analysis of ovarian serous cystadenomas. Lab Invest. 2004;84:778–84.

    Article  CAS  PubMed  Google Scholar 

  118. Ho C-L, Kurman RJ, Dehari R, Wang T-L, Shih I-M. Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res. 2004;64:6915–8.

    Article  CAS  PubMed  Google Scholar 

  119. Teneriello MG, Ebina M, Linnoila RI, et al. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res. 1993;53:3103–8.

    CAS  PubMed  Google Scholar 

  120. Mougeot J-L, Bahrani-Mostafavi Z, Vachris JC, et al. Gene expression profiling of ovarian tissues for determination of molecular pathways reflective of tumorigenesis. J Mol Biol. 2006;358:310–29.

    Article  CAS  PubMed  Google Scholar 

  121. Nicosia SV, Johnson JH, Streibel EJ. Growth characteristics of rabbit ovarian mesothelial (surface epithelial) cells. Int J Gynecol Pathol. 1985;4:58–74.

    Article  CAS  PubMed  Google Scholar 

  122. Siemens CH, Auersperg N. Serial propagation of human surface ovarian epithelium in tissue culture. J Cell Physiol. 1988;134:347–56.

    Article  CAS  PubMed  Google Scholar 

  123. Tsao SW, Mok SC, Fey EG, et al. Characterization of human ovarian surface epithelial cells immortalized by human papilloma viral oncogenes (HPV-E6E7). Exp Cell Res. 1995;218:499–507.

    Article  CAS  PubMed  Google Scholar 

  124. Yang G, Rosen DG, Mercado-Uribe I, et al. Knockdown of p53 with expression of the catalytic subunit of telomerase is sufficient to immortalize primary human ovarian surface epithelial cells. Carcinogenesis. 2006;28:174–82.

    Article  PubMed  Google Scholar 

  125. Dubeau L, Velicescu M, Sherrod AE, Schreiber G, Holt G. Culture of human fetal ovarian epithelium in a chemically-defined, serum-free medium. Anticancer Res. 1990;10:1233–40.

    CAS  PubMed  Google Scholar 

  126. Godwin AK, Testa JR, Handel LM, et al. Spontaneous transformation of rat ovarian surface epithelial cells: association with cytogenetic changes and implications of repeated ovulation in the etiology of ovarian cancer. J Natl Cancer Inst. 1992;84:592–601.

    Article  CAS  PubMed  Google Scholar 

  127. Crickard K, Marinello MJ, Crickard U, et al. Borderline malignant serous tumors of the ovary maintained on extracellular matrix. Evidence for clonal evolution and invasive potential. Cancer Genet Cyrogenet. 1986;23:135–43.

    CAS  Google Scholar 

  128. Luo MP, Gomperts B, Imren S, et al. Establishment of long-term in vitro cultures of human ovarian cystadenomas and LMP tumors and examination of their spectrum of expression of matrix-degrading proteinases. Gynecol Oncol. 1997;67:277–84.

    Article  CAS  PubMed  Google Scholar 

  129. Velicescu M, Yu J, Herbert BS, et al. Aneuploidy and telomere attrition are independent determinants of crisis in SV40-transformed epithelial cells. Cancer Res. 2003;63:5813–20.

    CAS  PubMed  Google Scholar 

  130. Yu J, Roy D, Dubeau L. Increased chromosomal stability of ovarian tumors of low malignant potential compared to cystadenomas. Br J Cancer. 2007;96:1908–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  131. Friedlander ML, Russell P, Taylor IW, Hedley DW, Tattersall MH. Flow cytometric analysis of cellular DNA content as an adjunct to the diagnosis of ovarian tumours of borderline malignancy. Pathology. 1984;16:301–6.

    Article  CAS  PubMed  Google Scholar 

  132. Lai CH, Hsueh S, Chang TC. The role of DNA flow cytometry in borderline malignant ovarian tumors. Cancer. 1996;78:794–802.

    Article  CAS  PubMed  Google Scholar 

  133. Burger CW, Prinssen HM, Baak JPA, Wagenaar N, Kenemans P. The management of borderline epithelial tumors of the ovary. Int J Gynecol Cancer. 2000;10:181–97.

    Article  PubMed  Google Scholar 

  134. Kaern J, Trope CG, Kjorstad KE, Abeler VM, Pettersen EO. Cellular DNA content as a new prognostic tool in patients with tumors of the ovary. Gynecol Oncol. 1990;38:452–7.

    Article  CAS  PubMed  Google Scholar 

  135. Sykes PH, Quinn MA, Rome RM. Ovarian tumors of low malignant potential: a retrospective study of 234 patients. Int J Gynecol Cancer. 1997;7:218–26.

    Article  Google Scholar 

  136. Dodson MK, Hartmann LC, Cliby WA, et al. Comparison of loss of heterozygosity patterns in invasive low-grade and high-grade epithelial ovarian carcinomas. Cancer Res. 1993;53:4456–60.

    CAS  PubMed  Google Scholar 

  137. Iwabuchi H, Sakamoto M, Sakunaga H, et al. Genetic analysis of benign, low-grade, and high-grade ovarian tumors. Cancer Res. 1995;55:6172–80.

    CAS  PubMed  Google Scholar 

  138. Zheng JP, Robinson WR, Ehlen T, Yu MC, Dubeau L. Distinction of low grade from high grade human ovarian carcinomas on the basis of losses of heterozygosity on chromosomes 3, 6, and 11 and HER-2/neu gene amplification. Cancer Res. 1991;51:4045–51.

    CAS  PubMed  Google Scholar 

  139. Kim TM, Benedict WF, Xu H-J, et al. Loss of heterozygosity on chromosome 13 is common only in the biologically more aggressive subtypes of ovarian epithelial tumors and is associated with normal retinoblastoma gene expression. Cancer Res. 1994;54:605–9.

    CAS  PubMed  Google Scholar 

  140. Dodson MK, Cliby WA, Xu H-J, et al. Evidence of functional RB protein in epithelial ovarian carcinomas despite loss of heterozygosity at the RB locus. Cancer Res. 1994;54:610–3.

    CAS  PubMed  Google Scholar 

  141. Ahmed AA, Etemadmoghadam D, Temple J, et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol. 2010;221:49–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  142. Vuento MH, Pirhonen JP, Makinen JI, Gronroos M, Salmi TA. Evaluation of ovarian findings in asymptomatic postmenopausal women with color Doppler ultrasound. Cancer. 1995;76:1214–8.

    Article  CAS  PubMed  Google Scholar 

  143. Chadwick BP, Lane TF. BRCA1 associates with the inactive X chromosome in late S-phase, coupled with transient H2AX phosphorylation. Chromosoma. 2005;114:432–9.

    Article  CAS  PubMed  Google Scholar 

  144. Ganesan S, Silver DP, Greenberg RA, et al. BRCA1 supports XIST RNA concentration on the inactive X chromosome. Cell. 2002;111:393–405.

    Article  CAS  PubMed  Google Scholar 

  145. Pageau GL, Hall LL, Lawrence JB. BRCA1 does not paint the inactive X to localize XIST RNA but may contribute to broad changes in cancer that impact XIST and Xi heterochromatin. J Cell Biochem. 2007;100:835–50.

    Article  CAS  PubMed  Google Scholar 

  146. Silver DP, Dimitrov SD, Feunteun J, et al. Further evidence for BRCA1 communication with the inactive X chromosome. Cell. 2007;128:991–1002.

    Article  CAS  PubMed  Google Scholar 

  147. Zheng J, Benedict WF, Xu H-J, et al. Genetic disparity between morphologically benign cysts contiguous to ovarian carcinomas and solitary cystadenomas. J Natl Cancer Inst. 1995;87:1146–53.

    Article  CAS  PubMed  Google Scholar 

  148. Zheng J, Wan M, Zweizig S, et al. Histologically benign or low-grade malignant tumors adjacent to high-grade ovarian carcinomas contain molecular characteristics of high-grade carcinomas. Cancer Res. 1993;53:4138–42.

    CAS  PubMed  Google Scholar 

  149. Wolf NG, Abdul-Karim FW, Schork NJ, Schwartz S. Origins of heterogeneous ovarian carcinomas. A molecular cytogenetic analysis of histologically benign, low malignant potential, and fully malignant components. Am J Pathol. 1996;149:511–20.

    CAS  PubMed  PubMed Central  Google Scholar 

  150. Shih IM, Kurman RJ. Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges. Clin Cancer Res. 2005;11:7273–379.

    Article  CAS  PubMed  Google Scholar 

  151. Berchuck A, Iversen ES, Lancaster JM, et al. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res. 2005;11:3686–96.

    Article  CAS  PubMed  Google Scholar 

  152. Horiuchi A, Itoh K, Shimizu M, et al. Towards understanding the natural history of ovarian carcinoma development: a clinicopathologic approach. Gynecol Oncol. 2003;88:309–17.

    Article  PubMed  Google Scholar 

  153. Skates SJ, Xu FJ, Yu YH, et al. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer. 1995;76:2004–10.

    Article  CAS  PubMed  Google Scholar 

  154. Jacobs IJ, Skates SJ, MacDonald N, et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet. 1999;353:1207–10.

    Article  CAS  PubMed  Google Scholar 

  155. Menon U, Skates SJ, Lewis S, et al. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol. 2005;23:7919–26.

    Article  PubMed  Google Scholar 

  156. Lu KH, Patterson AP, Wang L, et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res. 2004;10:3291–300.

    Article  CAS  PubMed  Google Scholar 

  157. Zhang Z, Bast Jr RC, Yu Y, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 2004;64:5882–90.

    Article  CAS  PubMed  Google Scholar 

  158. Gorelik E, Landsittel DP, Marrangoni AM, et al. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:981–7.

    Article  CAS  PubMed  Google Scholar 

  159. Gershenson DM, Copeland LJ, Wharton JT, et al. Prognosis of surgically determined complete responders in advanced ovarian cancer. Cancer. 1985;55:1129–35.

    Article  CAS  PubMed  Google Scholar 

  160. Muderspach L, Muggia FM, Conti PS. Second-look laparotomy for stage III epithelial ovarian cancer: rationale and current issues. Cancer Treat Rev. 1995;21:499–511.

    Article  Google Scholar 

  161. Podratz KC, Cliby WA. Second-look surgery in the management of epithelial ovarian carcinoma. Gynecol Oncol. 1994;55:S128–33.

    Article  CAS  PubMed  Google Scholar 

  162. Duggan BD, Wan M, Yu MC, et al. Detection of ovarian cancer cells: comparison of a telomerase assay and cytologic examination. J Natl Cancer Inst. 1998;90:238–42.

    Article  CAS  PubMed  Google Scholar 

  163. Nouriani M, Bahador A, Berek JS, et al. Detection of residual subclinical ovarian carcinoma after completion of adjuvant chemotherapy. Clin Cancer Res. 2004;10:2681–6.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division Gynecologic Oncology, Department of Pathology, USC/Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, 1441 Eastlake Avenue, Los Angeles, CA, 90033, USA

    Amy D. Brockmeyer M.D. & Louis Dubeau M.D., Ph.D.

Authors
  1. Amy D. Brockmeyer M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Louis Dubeau M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Louis Dubeau M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. Department of Pathology and Laboratory Medicine, Curriculum in Toxicology, UNC Program in Translational Medicine, UNC Lineberger Comprehensive Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA

    William B. Coleman

  2. Laboratory for Clinical Genomics and Advanced Technology (CGAT), Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, Hanover, New Hampshire, USA

    Gregory J. Tsongalis

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Science+Business Media New York

About this chapter

Cite this chapter

Brockmeyer, A.D., Dubeau, L. (2017). Ovarian Cancer. In: Coleman, W., Tsongalis, G. (eds) The Molecular Basis of Human Cancer. Humana Press, New York, NY. https://doi.org/10.1007/978-1-59745-458-2_33

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-458-2_33

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-934115-18-3

  • Online ISBN: 978-1-59745-458-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation